Deep vein thrombosis after monoclonal gammopathy of undetermined significance and multiple myeloma
Open Access
- 1 November 2008
- journal article
- research article
- Published by American Society of Hematology in Blood
- Vol. 112 (9), 3582-3586
- https://doi.org/10.1182/blood-2008-04-151076
Abstract
Patients with multiple myeloma (MM) have an increased risk of deep venous thrombosis (DVT), particularly when treated with immunomodulatory drugs. Recently, 2 small hospital-based studies observed persons with the MM precursor condition, monoclonal gammopathy of undetermined significance (MGUS), to be at increased risk of developing DVT. Among 4 196 197 veterans hospitalized at least once at US Veterans Affairs hospitals, we identified a total of 2374 cases of MGUS, and 39 272 persons were diagnosed with DVT (crude incidence 0.9 per 1000 person-years). A total of 31 and 151 DVTs occurred among MGUS and MM patients, respectively (crude incidence 3.1 and 8.7 per 1000 person-years, respectively; P < .01). Compared with the entire study population, the relative risk (RR) of DVT after a diagnosis of MGUS and MM was 3.3 (95% confidence interval [CI], 2.3-4.7) and 9.2 (95% CI, 7.9-10.8), respectively. The most prominent excess risk of DVT was found during the first year after diagnosis of MGUS (RR = 8.4; 95% CI, 5.7-12.2) and MM (RR = 11.6; 95% CI, 9.2-14.5). Among 229 MGUS cases (9.5%) that progressed to MM, only one person had a DVT diagnosis before transformation. Our findings suggest the operation of shared underlying mechanisms causing coagulation abnormalities among patients with MGUS and MM.Keywords
This publication has 36 references indexed in Scilit:
- Thrombomodulin levels are not modified during thalidomide treatmentEuropean Journal of Haematology, 2006
- Gene-expression signature of benign monoclonal gammopathy evident in multiple myeloma is linked to good prognosisBlood, 2006
- Acquired resistance to activated protein C (aAPCR) in multiple myeloma is a transitory abnormality associated with an increased risk of venous thromboembolismBritish Journal of Haematology, 2006
- Serum free light chain ratio is an independent risk factor for progression in monoclonal gammopathy of undetermined significanceBlood, 2005
- Venous thromboembolism: disease burden, outcomes and risk factorsJournal of Thrombosis and Haemostasis, 2005
- The risk of venous thromboembolic disease in patients with monoclonal gammopathy of undetermined significanceAnnals Of Oncology, 2004
- Monoclonal gammopathy of undetermined significance and multiple myeloma are associated with an increased incidence of venothromboembolic diseaseCancer, 2004
- Deep-vein thrombosis in patients with multiple myeloma receiving first-line thalidomide-dexamethasone therapyBlood, 2002
- The Risk of a Diagnosis of Cancer after Primary Deep Venous Thrombosis or Pulmonary EmbolismNew England Journal of Medicine, 1998
- Occasional Survey: SOURCE OF NON-LETHAL PULMONARY EMBOLIThe Lancet, 1974